Advertisement

Topics

Final stretch

14:06 EDT 4 Aug 2017 | BioCentury

Dynavax and FDA must determine how to design a CV study of Heplisav-B that can quickly enroll high-risk patients while controlling for bias.

Original Article: Final stretch

NEXT ARTICLE

More From BioPortfolio on "Final stretch"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...